Besides some contradictory results [54]–[56], the European Group of Tumor Markers (EGTM) and the American Society of Clinical Oncology (ASCO) did not recommend p53 mutation detection for screening, diagnosis, staging, surveillance, determining prognosis or monitoring treatment of patients with CRC [57], [58]. This evidence concerns the gene TP53 and neoplasm.